Artem A. Babasinov
Artem A. Babasinov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Eduard Evgenievich Rostorguev
National Medical Research Centre for Oncology, Rostov-on-Don, Russia
3 shared publications - Irina Aleksandrovna Goroshinskaya
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
3 shared publications - Irina Viktorovna Kaplieva
Rostov Research Institute of Oncology
3 shared publications - Lidiya Konstantinovna Trepitaki
National Medical Research Center for Oncology, Ministry of Health of Russia
2 shared publications - Lyudmila Ya. Rozenko
National Medical Research Centre for Oncology
2 shared publications - Stanislav G. Vlasov
National Medical Research Centre for Oncology, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (2) , 119-124
Effect of different variants of radiation treatment on the parameters of tissue plasminogen activator and its inhibitor in the blood of patients with metastatic brain lesions
Background. The prevalence of metastatic brain tumors (MBT), accompanied by high mortality and limited treatment options associated with the localization of the process, underscores the importance of studying the metabolic systems involved in the progression of malignant disease and sensitivity to antitumor treatment. One such system is the fibrinolytic system, which comprises a series of activators, inhibitors, and receptors. Aim. To examine the levels and activities of tissue plasminogen activator (tPA), as well as fibrinolysis inhibitor, in the blood of patients with MBT who are undergoing various radiotherapeutic treatments. Materials and methods. The activity and content of tPA and type 1 plasminogen activator inhibitor (PAI-1) were studied in the blood plasma of 38 patients with MBT by enzyme-linked immunosorbent assay. The results were compared with the data of 18 people without oncologic pathology (donor group). Three groups were formed according to the treatment options: Control group – stereotactic radiotherapy on the place of the removed metastasis with a single focal dose (SFD) of 6 Gy up to a total dose of 30 Gy; Main group No. 1 – after a session of preoperative radiosurgery with a SFD of 10–15 Gy, the metastatic focus was removed 24 hours later; Main group No. 2 – staged radiosurgery (SRS) was performed in 3 stages with a SFD of 10 Gy and an interval between sessions of 14 days (total 30 Gy). Results. For patients with metastatic brain lesions, before the start of treatment, a 2.1-fold increase in tPA activity was typical, with a 3.6-fold decrease in its content, leading to a 10-fold increase in their ratio. In the control group, tPA activity remained elevated 3 days after surgery, after a month it did not differ from the level in donors, and the tPA content was reduced. In both main groups, a heightened level of tPA activity was observed throughout the observation period. After one month, this activity was found to be 2.6 times higher compared to the control group (p≤0.001). Only patients receiving SRS were characterized by an increase in the initially decreased tPA content, accompanied by a shift towards normalization of the ratio of tPA activity to its content. This was concomitant with an increase in PAI-1 activity, reaching the donor level. Conclusion. The identified dynamics of tPA parameters may contribute to the clinical efficacy of SRS.
- 10 April 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (2) , 119-124
Open AccessEffect of different variants of radiation treatment on the parameters of tissue plasminogen activator and its inhibitor in the blood of patients with metastatic brain lesions
Background. The prevalence of metastatic brain tumors (MBT), accompanied by high mortality and limited treatment options associated with the localization of the process, underscores the importance of studying the metabolic systems involved in the progression of malignant disease and sensitivity to antitumor treatment. One such system is the fibrinolytic system, which comprises a series of activators, inhibitors, and receptors. Aim. To examine the levels and activities of tissue plasminogen activator (tPA), as well as fibrinolysis inhibitor, in the blood of patients with MBT who are undergoing various radiotherapeutic treatments. Materials and methods. The activity and content of tPA and type 1 plasminogen activator inhibitor (PAI-1) were studied in the blood plasma of 38 patients with MBT by enzyme-linked immunosorbent assay. The results were compared with the data of 18 people without oncologic pathology (donor group). Three groups were formed according to the treatment options: Control group – stereotactic radiotherapy on the place of the removed metastasis with a single focal dose (SFD) of 6 Gy up to a total dose of 30 Gy; Main group No. 1 – after a session of preoperative radiosurgery with a SFD of 10–15 Gy, the metastatic focus was removed 24 hours later; Main group No. 2 – staged radiosurgery (SRS) was performed in 3 stages with a SFD of 10 Gy and an interval between sessions of 14 days (total 30 Gy). Results. For patients with metastatic brain lesions, before the start of treatment, a 2.1-fold increase in tPA activity was typical, with a 3.6-fold decrease in its content, leading to a 10-fold increase in their ratio. In the control group, tPA activity remained elevated 3 days after surgery, after a month it did not differ from the level in donors, and the tPA content was reduced. In both main groups, a heightened level of tPA activity was observed throughout the observation period. After one month, this activity was found to be 2.6 times higher compared to the control group (p≤0.001). Only patients receiving SRS were characterized by an increase in the initially decreased tPA content, accompanied by a shift towards normalization of the ratio of tPA activity to its content. This was concomitant with an increase in PAI-1 activity, reaching the donor level. Conclusion. The identified dynamics of tPA parameters may contribute to the clinical efficacy of SRS.
- Open Access
- 13 March 2026
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 7 (1) , 24-38
The influence of radiation treatment options on the urokinase system of plasminogen activation in the blood of patients with metastatic brain lesions
Влияние вариантов лучевого лечения на урокиназную систему активации плазминогена в крови больных с метастатическим поражением головного мозга
- 13 March 2026
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 7 (1) , 24-38
Open AccessThe influence of radiation treatment options on the urokinase system of plasminogen activation in the blood of patients with metastatic brain lesions
Влияние вариантов лучевого лечения на урокиназную систему активации плазминогена в крови больных с метастатическим поражением головного мозга
- Open Access
- 9 September 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (3) , 35-44
Preliminary Results of Two-Stage Radiosurgery for Brain Metastases
Purpose of the study. To perform a preliminary assessment of local control after two-stage staged radiosurgery in patients with metastatic brain lesions.Patients and methods. For staged radiosurgery, large lesions measuring ≥ 3 cm in the largest dimension were selected. The regimen consisted of delivering 12 Gy in a single fraction at the first stage and 14 Gy in a single fraction at the second stage, with a 14‑day interval between the stages. If additional smaller lesions were present, they were irradiated simultaneously using the standard SRS technique in a single fraction with a dose per fraction (DPF) of 18–24 Gy. The prospective analysis included 32 patients of both sexes aged 34 to 76 years (mean age 57 ± 3.3 years) with brain metastatic lesions ≥ 3 cm in the largest dimension, or located in close proximity to critical brain structures, who underwent a two-stage course of staged radiosurgery at the National Medical Research Centre for Oncology.Results. The evaluation of target lesion volumes was based on brain MRI performed before treatment, prior to the second stage, and one month after completion of treatment. At the one-month follow-up after the treatment course, local control was achieved in the vast majority of clinical cases. Sixteen lesions demonstrated a volume reduction of more than 70 % from baseline, eleven showed a reduction of more than 50 %, eight lesions exhibited a decrease of less than 50 %, and one lesion demonstrated a negative response.Conclusion. Two-stage staged radiosurgery for brain metastases demonstrated satisfactory local control in patients with various primary tumor sites. The positive dynamics observed at this stage suggest the potential for favorable long-term outcomes.
- 9 September 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (3) , 35-44
Open AccessPreliminary Results of Two-Stage Radiosurgery for Brain Metastases
Purpose of the study. To perform a preliminary assessment of local control after two-stage staged radiosurgery in patients with metastatic brain lesions.Patients and methods. For staged radiosurgery, large lesions measuring ≥ 3 cm in the largest dimension were selected. The regimen consisted of delivering 12 Gy in a single fraction at the first stage and 14 Gy in a single fraction at the second stage, with a 14‑day interval between the stages. If additional smaller lesions were present, they were irradiated simultaneously using the standard SRS technique in a single fraction with a dose per fraction (DPF) of 18–24 Gy. The prospective analysis included 32 patients of both sexes aged 34 to 76 years (mean age 57 ± 3.3 years) with brain metastatic lesions ≥ 3 cm in the largest dimension, or located in close proximity to critical brain structures, who underwent a two-stage course of staged radiosurgery at the National Medical Research Centre for Oncology.Results. The evaluation of target lesion volumes was based on brain MRI performed before treatment, prior to the second stage, and one month after completion of treatment. At the one-month follow-up after the treatment course, local control was achieved in the vast majority of clinical cases. Sixteen lesions demonstrated a volume reduction of more than 70 % from baseline, eleven showed a reduction of more than 50 %, eight lesions exhibited a decrease of less than 50 %, and one lesion demonstrated a negative response.Conclusion. Two-stage staged radiosurgery for brain metastases demonstrated satisfactory local control in patients with various primary tumor sites. The positive dynamics observed at this stage suggest the potential for favorable long-term outcomes.
- Open Access
- 18 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 24-33
Redox Status of the Blood of Patients with Metastatic Brain Lesion During Different Options of Radiotherapeutic Treatment
Purpose: A comparative study of the content of lipid peroxidation (LPO) products and the activity of the main antioxidant enzymes in the blood plasma of patients with brain metastases (BM) under various radiotherapeutic treatment options.Material and methods: The study included 37 patients with BM. Three groups of patients were formed: Control group (12 patients), in which stereotactic radiotherapy with a single focal dose of 6 Gy to a total dose of 30 Gy was performed on the place of the removed metastasis; Main group No. 1 (6 patients) — after a session of preoperative radiosurgery with a dose of 10-15 Gy, the metastatic focus was removed after 24 hours; Main group No. 2 (19 patients) — staged radiosurgery (SRS) was carried out in 3 stages with a dose of 10 Gy with an interval between sessions of 14 days (total dose of 30 Gy). In the blood plasma of 37 patients, the content of malondialdehyde (MDA), diene conjugates (DC), and the activity of superoxide dismutase and catalase were determined by standard spectrophotometric methods. The comparison group included 21 people without cancer (donors). Statistical processing of the results was carried out using the Statistica 10.0 program. using Student’s t-test and nonparametric Mann–Whitney test.Results: Before treatment, the MDA content was increased in all patients, on average by 83.5 % (p = 0.00025) relative to the donor group; in the majority, DC was also increased (by 60.4 %, p = 0.0498). After removal of the metastatic lesion in patients in the Control and Main group No. 1, the level of LPO products remained elevated. And only in the Main Group No. 2, already before the 3rd session of SRS, a decrease in the level of MDA was observed in patients with a removed primary lesion, as well as normalization of DC in all patients and restoration of the coordinated work of antioxidant enzymes. An increase in MDA content with reduced catalase activity in patients with an unremoved primary lesion at the stages of SRS may reflect the mechanism of tumor cell reduction under the influence of increased production of free radicals during long-term radiation exposure.Conclusions: The use of SRS, in contrast to other radiotherapy options, helps to normalize the redox status of the blood of patients with metastatic brain lesions. Analysis of the data obtained suggests greater effectiveness of SRS in patients with a removed primary lesion.
- 18 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 24-33
Open AccessRedox Status of the Blood of Patients with Metastatic Brain Lesion During Different Options of Radiotherapeutic Treatment
Purpose: A comparative study of the content of lipid peroxidation (LPO) products and the activity of the main antioxidant enzymes in the blood plasma of patients with brain metastases (BM) under various radiotherapeutic treatment options.Material and methods: The study included 37 patients with BM. Three groups of patients were formed: Control group (12 patients), in which stereotactic radiotherapy with a single focal dose of 6 Gy to a total dose of 30 Gy was performed on the place of the removed metastasis; Main group No. 1 (6 patients) — after a session of preoperative radiosurgery with a dose of 10-15 Gy, the metastatic focus was removed after 24 hours; Main group No. 2 (19 patients) — staged radiosurgery (SRS) was carried out in 3 stages with a dose of 10 Gy with an interval between sessions of 14 days (total dose of 30 Gy). In the blood plasma of 37 patients, the content of malondialdehyde (MDA), diene conjugates (DC), and the activity of superoxide dismutase and catalase were determined by standard spectrophotometric methods. The comparison group included 21 people without cancer (donors). Statistical processing of the results was carried out using the Statistica 10.0 program. using Student’s t-test and nonparametric Mann–Whitney test.Results: Before treatment, the MDA content was increased in all patients, on average by 83.5 % (p = 0.00025) relative to the donor group; in the majority, DC was also increased (by 60.4 %, p = 0.0498). After removal of the metastatic lesion in patients in the Control and Main group No. 1, the level of LPO products remained elevated. And only in the Main Group No. 2, already before the 3rd session of SRS, a decrease in the level of MDA was observed in patients with a removed primary lesion, as well as normalization of DC in all patients and restoration of the coordinated work of antioxidant enzymes. An increase in MDA content with reduced catalase activity in patients with an unremoved primary lesion at the stages of SRS may reflect the mechanism of tumor cell reduction under the influence of increased production of free radicals during long-term radiation exposure.Conclusions: The use of SRS, in contrast to other radiotherapy options, helps to normalize the redox status of the blood of patients with metastatic brain lesions. Analysis of the data obtained suggests greater effectiveness of SRS in patients with a removed primary lesion.